Cargando…
P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB-BASED ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
Autores principales: | Meinke, S., Kadri, N., Bi, S., Bostancioglu, B., Markey, C., Breitmeyer, J. B., Hussain, A., Krishnan, R., Kaufmann, G. F., Alici, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429158/ http://dx.doi.org/10.1097/01.HS9.0000848596.52159.85 |
Ejemplares similares
-
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells
por: Liu, Dongli, et al.
Publicado: (2022) -
P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Yazji, S., et al.
Publicado: (2022) -
P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE
por: Wang, M., et al.
Publicado: (2022) -
Abstracts from USCAP 2019: Infectious Disease Pathology (1435-1462)
Publicado: (2019) -
Abstracts from USCAP 2019: Infectious Disease Pathology (1435-1462)
Publicado: (2019)